Your shopping cart is currently empty

AC-186 is a nonsteroidal estrogen receptor β (ERβ) agonist with different affinities for ERβ and ERα, with an EC50 of 6 nM for ERβ and 5000 nM for ERα. AC-186 has neuroprotective activity and has been used in the study of Parkinson's disease.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $41 | In Stock | In Stock | |
| 5 mg | $106 | In Stock | In Stock | |
| 10 mg | $159 | In Stock | In Stock | |
| 25 mg | $289 | In Stock | In Stock | |
| 50 mg | $438 | In Stock | In Stock | |
| 100 mg | $658 | - | In Stock | |
| 200 mg | $919 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $117 | In Stock | In Stock |
| Description | AC-186 is a nonsteroidal estrogen receptor β (ERβ) agonist with different affinities for ERβ and ERα, with an EC50 of 6 nM for ERβ and 5000 nM for ERα. AC-186 has neuroprotective activity and has been used in the study of Parkinson's disease. |
| Targets&IC50 | ERα:5000 nM (EC50), ERβ:6 nM (EC50) |
| In vitro | In LNCaP cells, AC-186 (10 μM; 72 hours) inhibits the growth of LNCaP cells[1]. |
| In vivo | In male Sprague-Dawley rats weighing 225-250 g, AC-186 (10 mg/kg; s.c.; once) prevented motor, cognitive, and sensorimotor gating deficits and mitigated the loss of dopamine neurons in the substantia nigra, but had no effect in females[1]. |
| Synonyms | AC186, AC 186 |
| Molecular Weight | 306.32 |
| Formula | C18H17F3O |
| Cas No. | 1421854-16-1 |
| Smiles | FC=1C=CC=CC1C2(C3=CC=C(O)C=C3)CCC(F)(F)CC2 |
| Relative Density. | no data available |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (261.16 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (10.77 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.